SLC22A1 and hepatocellular carcinoma: Low intratumoral OCT1 expression was reported to be associated with a worse survival of patients with hepatocellular carcinoma (HCC), while presence of the transporter at the plasma membrane was beneficial for therapy response [30,31] (Table 2).